DarioHealth Corp. announced that Dr. Marilyn Ritholz and Dr. David Horwitz will join Chairman Eric Milledge on its Scientific Advisory Board (SAB), advancing Dario's technical leadership and helping to guide the development of its bold technology roadmap. Dr. Ritholz and Dr. Horwitz are recognized for their expertise in diabetes, metabolism, and behavioral health. The SAB mission is to advance Dario's DTx platform by integrating members' comprehensive experience and expertise into Dario's offering. The SAB will work with Dario's clinical and commercial teams to broaden and strengthen Dario's offering for the management of chronic conditions. They anticipate that the assistance of the SAB will help promote increased stakeholder awareness and deeper market penetration of the Dario platform, in addition to improving the health of individuals. They believe that combining the Dario research and development (R&D) team and the SAB's expertise further strengthens Dario's next-generation, AI-powered, digital therapeutic solutions and advances its approach of supporting more than just an individual's disease. Dario provides adaptive, personalized experiences that drive behavior change through intuitive, clinically proven digital tools and coaching to help individuals improve health and sustain meaningful outcomes. Dr. Ritholz is a Senior Psychologist at the Joslin Diabetes Center and treats both adults and adolescents with diabetes. In addition, she is on the faculty at Beth Israel Deaconess Medical Center (BIDMC) and is an Assistant Professor of Psychology at Harvard Medical School. Dr. Ritholz is an experienced qualitative researcher. In collaboration with colleagues, she has explored qualitative aspects of healthcare regarding the patient-provider relationship, provider communication about diabetes complications, and psychosocial factors associated with diabetes technology, including continuous glucose monitoring. She has published more than 20 qualitative articles on these topics. Dr. Horwitz is presently a Senior Consultant with Numerof & Associates and also President of DLH Biomedical Consulting. He previously served as the Global Chief Medical Officer of the Johnson and Johnson Diabetes Institute.